Pellegrin Hospital

The Service des Maladies Infectieuses et Tropicales at Pellegrin Hospital advances the treatment of viral, bacterial and fungal infections, focusing on conditions such as HIV, severe sepsis and community‑acquired pneumonia.

• Innovative antiretroviral strategies for HIV cure research
• Optimizing antibiotic regimens to combat sepsis and antimicrobial resistance
• Vaccine development and evaluation for emerging tropical pathogens
• Novel antiviral agents targeting respiratory viruses
• Surveillance programs for drug‑resistant bacterial infections

The department collaborates closely with regional health agencies, enrolling a growing number of patients across diverse infectious disease trials.

Research at the site covers a broad spectrum of cancers, from common solid tumors to rare sarcomas and hematologic malignancies, including synovial sarcoma, advanced melanoma and various forms of lymphoma.

• Precision medicine approaches for rare sarcoma subtypes
• Immunotherapy combinations for resectable mucosal melanoma
• CAR‑T cell therapy evaluation in B‑cell acute lymphoblastic leukemia and non‑Hodgkin lymphoma
• Targeted inhibitors for castration‑resistant prostate cancer
• Add‑on mifamurtide to standard chemotherapy for high‑risk osteosarcoma

With 55 active trials and 60 investigators, the oncology program integrates a multidisciplinary tumor board to guide patient enrollment and data sharing.

The hospital’s neurology portfolio investigates acute cerebrovascular events and chronic neurodegenerative diseases such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease.

• Reperfusion and neuroprotective strategies for acute ischemic stroke
• Disease‑modifying therapies for relapsing and primary progressive multiple sclerosis
• Early‑stage intervention trials in Parkinson’s disease
• Novel agents targeting frontotemporal dementia and Alzheimer’s disease progression
• Functional outcome assessments after subarachnoid hemorrhage

Patient‑focused endpoints, including cognitive and motor function, guide the evaluation of therapeutic impact.

Dedicated renal research addresses kidney transplantation, graft rejection and glomerular diseases, with emphasis on antibody‑mediated rejection and IgA nephropathy.

• Biologic agents to prevent and treat antibody‑mediated rejection
• Personalized rituximab dosing algorithms driven by therapeutic drug monitoring
• Targeted therapies for IgA nephropathy and membranous nephropathy
• Management strategies for gout in patients with advanced renal impairment
• Long‑term safety monitoring of novel immunosuppressive regimens

The renal unit works in tandem with nephrology and transplant surgery teams to ensure comprehensive follow‑up.

Trials explore treatments for inherited and ultra‑rare conditions, including Pompe disease, primary hyperoxaluria and transthyretin amyloidosis.

• Enzyme replacement and gene‑therapy approaches for Pompe disease
• RNA‑interference therapies to reduce oxalate production in primary hyperoxaluria
• TTR stabilizers and gene‑silencing agents for transthyretin amyloidosis
• Metabolic control interventions for obesity and overweight populations
• Collaborative registries for rare disease patient outcomes

The site participates in national rare‑disease networks, facilitating access to cutting‑edge therapies.

Cardiovascular research targets atherosclerotic disease, heart failure and stroke prevention, with studies on atherosclerotic cardiovascular disease and acute cerebral ischemia.

• Antiplatelet and P2Y12 inhibitor strategies after mechanical thrombectomy
• GLP‑1 receptor agonists for reducing major adverse cardiovascular events
• Blood‑flow modulation in Raynaud phenomenon and peripheral vascular disease
• Evaluation of novel agents to lower cardiovascular mortality in high‑risk patients
• Integrated care pathways for stroke survivors to improve functional outcomes

Findings are shared with French cardiology societies to inform clinical guidelines.